PMV Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $69.9M | $58.5M | $55.9M | $52.0M | $36.5M |
| Operating expenses | $86.2M | $85.4M | $80.1M | $77.0M | $58.3M |
| Operating income | -$86.2M | -$85.4M | -$80.1M | -$77.0M | -$58.3M |
| Pretax income | -$79.9M | -$74.8M | -$69.0M | -$73.3M | -$57.8M |
| Income tax expense | -$2.2M | -$16.1M | $2,000 | -$9,000 | $23,000 |
| Net income | -$77.7M | -$58.7M | -$69.0M | -$73.3M | -$57.8M |
| Balance Sheet | |||||
| Cash and equivalents | $38.0M | $40.9M | $37.7M | $108.3M | $172.5M |
| Current assets | $115.2M | $175.7M | $207.4M | $247.0M | $301.3M |
| Total assets | $116.6M | $191.3M | $252.2M | $270.3M | $331.6M |
| Current liabilities | $11.4M | $14.4M | $14.0M | $10.8M | $12.2M |
| Total liabilities | $11.8M | $15.2M | $26.5M | $24.3M | $23.0M |
| Stockholders' equity | $104.7M | $176.1M | $225.7M | $246.0M | $308.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$73.6M | -$51.3M | -$55.7M | -$63.8M | -$46.6M |
| Depreciation and amortization | $133,000 | $1.1M | $1.3M | $315,000 | $307,000 |
| Stock-based compensation | $5.9M | $8.9M | $12.4M | $10.2M | $5.3M |
| Capital expenditure | $29,000 | $655,000 | $962,000 | $8.0M | $1.3M |
| Free cash flow | -$73.6M | -$51.9M | -$56.6M | -$71.7M | -$47.9M |
| Dividends paid | $0 | $0 | — | $0 | $0 |
Shares outstanding 53.3M · Free float 79.8%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.